Answers are grounded in this paper and cite their sources.
5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usually well tolerated, toxicity can be severe, and even life-threatening. A dihydropyrimidine dehydrogenase (DPD) deficiency can cause severe toxicity. Current testing for DPD deficiency does not meet the criteria for a routine screening test prior to 5-FU therapy. A case study of a fatality secondary to capecitabine toxicity is reviewed and literature is examined regarding general screening for DPD deficiency.
No takes yet. Share an insight, caveat, or question.
Vogel et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: